Abstract
Charcot-Marie-Tooth disease type 2A (CMT2A) is one of the subdivisions of CMT2, an axonal defective form of peripheral neuropathy. Different mutations in the mitochondrial GTPase mitofusin 2 (MFN2) gene produce various degrees of severity of CMT2A phenotype or CMT2A related hereditary motor and sensory neuropathy VI (HMSN VI). The occurrence of de novo mutations in MFN2 is by far the most frequent as compared to other CMT genes. About 26% of the pathogenic MFN2 mutations reported in the Inherited Peripheral Neuropathies Mutations Database are de novo. This study identified two de novo mutations of MFN2, c.1048T>C (S350P) and c.310C>T (R104W), from two Korean CMT2A patients with early onset severe clinical symptoms. The comparative genotype-phenotype correlations of these mutations according to a previously reported case were also viewed. The R104W mutation has been reported recurrently, outspread over different ethnic backgrounds as de novo. The re-occurrence of the same pathogenic de novo variants within and amongst different ethnic groups clearly suggests a susceptible hot spot for mutation in the MFN2 gene. If the deleterious mutations discourage fitness and reproduction, this negative selection factor should ultimately reduce the prevalence of the disease. It appears that spontaneous de novo mutations in turn seem to be maintaining the disease phenotype’s prevalence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Awadalla P, Gauthier J, Myers RA, Casals F, Hamdan FF, Griffing AR, Côté M, Henrion E, Spiegelman D, Tarabeux J, et al. (2010) Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Am. J. Hum. Genet. 87: 316–324.
Bienfait HM, Baas F, Koelman JH, de Haan RJ, van Engelen BG, Gabreëls-Festen AA, Ongerboer de Visser BW, Meggouh F, Weterman MA, et al. (2007) Phenotype of Charcot-Marie-Tooth disease Type 2. Neurology 68: 1658–1667.
Birouk N, LeGuern E, Maisonobe T, Rouger H, Gouider R, Tardieu S, Gugenheim M, Routon MC, Léger JM, Agid Y, et al. (1998) X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study. Neurology 50: 1074–1082.
Bissar-Tadmouri N, Nelis E, Züchner S, Parman Y, Deymeer F, Serdaroglu P, De Jonghe P, Van Gerwen V, Timmerman V, Schröder JM, et al. (2004) Absence of KIF1B mutation in a large Turkish CMT2A family suggests involvement of a second gene. Neurology 62: 1522–1525.
Brockmann K, Dreha-Kulaczewski S, Dechent P, Bönnemann C, Helms G, Kyllerman M, Brück W, Frahm J, Huehne K, Gärtner J, et al. (2008) Cerebral involvement in axonal Charcot-Marie-Tooth neuropathy caused by mitofusin 2 mutations. J. Neurol. 55: 1049–1058.
Calvo J, Funalot B, Ouvrier RA, Lazaro L, Toutain A, De Mas P, Bouche P, Gilbert-Dussardier B, Arne-Bes MC, Carrière JP, et al. (2009) Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. Arch. Neurol. 66:1511–1516.
Cartoni R and Martinou JC (2009) Role of mitofusin 2 mutations in the physiopathology of Charcot-Marie-Tooth disease type 2A. Exp. Neurol. 218: 268–273.
Casasnovas C, Banchs I, Cassereau J, Gueguen N, Chevrollier A, Martínez-Matos JA, Bonneau D and Volpini V (2010) Phenotypic spectrum of MFN2 mutations in the Spanish population. J. Med. Genet. 47: 249–256.
Cho HJ, Sung DH, Kim BJ and Ki CS (2007) Mitochondrial GTPase mitofusin 2 mutations in Korean patients with Charcot-Marie-Tooth neuropathy type 2. Clin. Genet. 71: 267–272.
Choi B-O, Lee MS, Shin SH, Hwang JH, Choi K-G, Kim W-K, Sunwoo IN, Kim NK, Chung KW (2007) Mutational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-Marie-Tooth neuropathy patients. Hum. Mutat. 24: 185–186.
Chung KW, Kim SB, Park KD, Choi KG, Lee JH, Eun HW, Suh JS, Hwang JH, Kim WK, Seo BC, et al. (2006) Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain 129: 2103–2118.
Chung KW, Suh BC, Shy ME, Cho SY, Yoo JH, Park SW, Moon H, Park KD, Choi KG, Kim S, et al. (2008) Different clinical and magnetic resonance imaging features between Charcot-Marie-Tooth disease type 1A and 2A. Neuromuscul. Disord. 18: 610–618.
Del Bo R, Moggio M, Rango M, Bonato S, D’Angelo MG, Ghezzi S, Airoldi G, Bassi MT, Guglieri M, Napoli L, et al. (2008) Mutated mitofusin 2 presents with intrafamilial variability and brain mitochondrial dysfunction. Neurology 71: 1959–1966.
De Jonghe P, Timmerman V, Broeckhoven CV, and workshop participants (1997) 2nd Workshop of the European CMT Consortium: 53rd ENMC International Workshop on Classification and Diagnostic Guidelines for Charcot-Marie-Tooth Type 2 (CMT2HMSN II) and Distal Hereditary Motor Neuropathy (Distal HMNSpinal CMT): Neuromusc. Disord. 1998: 426–431.
DeLisi LE, Shaw SH, Crow TJ, Shields G, Smith AB, Larach VW, Wellman N, Loftus J, Nanthakumar B, Razi K, et al. (2002) A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159: 803–812.
Eklund E, Svensson E and Häger-Ross C (2009) Hand function and disability of the arm, shoulder and hand in Charcot-Marie-Tooth disease. Disabil. Rehabil. 31: 1955–1962.
Gallardo E, García A, Combarros O and Berciano J (2006) Charcot-Marie-Tooth disease type 1A duplication: spectrum of clinical and magnetic resonance imaging features in leg and foot muscles. Brain 129: 426–437.
Genari AB, Borghetti VH, Gouvêa SP, Bueno KC, dos Santos PL, dos Santos AC, Barreira AA, Lourenço CM and Marques W Jr (2011) Characterizing the phenotypic manifestations of MFN2 R104W mutation in Charcot-Marie-Tooth type 2. Neuromuscul. Disord. 21: 428–432.
Julie G, Hamdan FF and Rouleau GA (2011) A strategy to identify de novo mutations in common disorders such as autism and schizophrenia. J. Vis. Exp. pii: 2534.
Kijima K, Numakura C, Izumino H, Umetsu K, Nezu A, Shiiki T, Ogawa M, Ishizaki Y, Kitamura T, Shozawa Y, et al. (2005) Mitochondrial GTPase mitofusin 2 mutation in Charcot-Marie-Tooth neuropathy type 2A. Hum. Genet. 116: 23–27.
Knott AB, Perkins G, Schwarzenbacher R and Bossy-Wetzel E (2008) Mitochondrial fragmentation in neurodegeneration. Nat. Rev. Neurosci. 9: 505–518.
Kondrashov AS (2003) Direct estimates of human per nucleotide mutation rates at 20 loci causing Mendelian diseases. Hum. Mutat. 21: 12–27.
Koshiba T, Detmer SA, Kaiser JT, Chen H, McCaffery JM and Chan DC (2004) Structural basis of mitochondrial tethering by mitofusin complexes. Science 305: 858–862.
Kryukov GV, Pennacchio LA and Sunyaev SR (2007) Most rare missense alleles are deleterious in humans: Implications for complex disease and association studies. Am. J. Hum. Genet. 80: 727–739.
Lee JH, Kang HJ, Song H, Hwang SJ, Cho SY, Kim SB, Kim J, Chung KW and Choi BO (2007) A family harboring CMT1A duplication and HNPP deletion. J. Clin. Neurol. 3: 101–104.
Meeusen S, McCaffery JM and Nunnari J (2004) Mitochondrial fusion intermediates revealed in vitro. Science 305: 1747–1752.
Polke JM, Laurá M, Pareyson D, Taroni F, Milani M, Bergamin G, Gibbons VS, Houlden H, Chamley SC, Blake J, et al. (2011) Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology 77: 168–173.
Roach JC, Glusman G, Smit AF, Huff CD, Hubley R, Shannon PT, Rowen L, Pant KP, Goodman N and Bamshad M (2010) Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 328: 636–639.
Rutter M (2005) Incidence of autism spectrum disorders: Changes over time and their meaning. Acta. Paediatr. 94: 2–15.
Saha S, Chant D, Welham J and McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med. 2: e141.
Santel A and Fuller MT (2001) Control of mitochondrial morphology by a human mitofusin. J. Cell Sci. 114: 867–874.
Shy ME (2004) Charcot-Marie-Tooth disease: an update. Curr. Opin. Neurol. 17: 579–585.
Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, Li J, Lewis RA and Reilly M (2005) Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64: 1209–1214.
Saito M, Hayashi Y, Suzuki T, Tanaka H, Hozumi I and Tsuji S (1997) Linkage mapping of the gene for Charcot-Marie-Tooth disease type 2 to chromosome 1p (CMT2A) and the clinical features of CMT2A. Neurology 49: 1630–1635.
Verhoeven K, Claeys KG, Züchner S, Schröder JM, Weis J, Ceuterick C, Jordanova A, Nelis E, De Vriendt E, Van Hul M, et al. (2006) MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 129: 2093–2102.
Zhao C, Takita J, Tanaka Y, Setou M, Nakagawa T, Takeda S, Yang HW, Terada S, Nakata T, Takei Y, et al. (2001) Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1B-beta. Cell 105: 587–597.
Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, et al. (2004) Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat. Genet. 36: 449–451.
Züchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, Hamilton SR, Van Stavern G, Krajewski KM, Stajich J, et al. (2006) Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann. Neurol. 59: 276–281.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Nakhro, K., Kim, Y.J., Lee, J.H. et al. Two de novo mutations of MFN2 associated with early-onset Charcot-Marie-Tooth disease type 2A neuropathy. Genes Genom 34, 653–661 (2012). https://doi.org/10.1007/s13258-012-0087-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13258-012-0087-8